Eiger BioPharmaceuticals (STU:72C) Tax Rate %: -0.01% (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Tax Rate %?

Eiger BioPharmaceuticals STU:72C 10 Tax Rate % is -0.01% as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Eiger BioPharmaceuticals's Tax Expense for the six months ended in Dec. 2023 was €0.00 Mil. Eiger BioPharmaceuticals's Pre-Tax Income for the six months ended in Dec. 2023 was €-28.87 Mil. Therefore, Eiger BioPharmaceuticals's Tax Rate % for the quarter that ended in Dec. 2023 was -0.01%.

Eiger BioPharmaceuticals Tax Rate % Related Terms

Eiger BioPharmaceuticals Tax Rate % Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Tax Rate % Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.19 -0.02 -0.01

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.01 -0.01 -0.01 0.00
STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Eiger BioPharmaceuticals's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0.006/-68.736
=-0.01 %

Eiger BioPharmaceuticals's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2023 )/Pre-Tax Income (Q: Dec. 2023 )
=0.002/-28.869
=-0.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of -0.01% mean?
Eiger BioPharmaceuticals (STU:72C) has a Tax Rate % of -0.01% as of Dec. 2023.
Is Eiger BioPharmaceuticals' Tax Rate % too high?
Eiger BioPharmaceuticals' current Tax Rate % is -0.01%. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Tax Rate % compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Tax Rate % of -0.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Eiger BioPharmaceuticals's current Tax Rate % is -0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Tax Rate % of -0.01%. The current Tax Rate % is -0.01%. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Tax Rate % is -0.01% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price